BioInvent International
LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV)
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The solid balance sheet and strong, loyal shareholders support us in achieving our goals," said Martin Welschof, BioInvent CEO.
Events in the quarter
• (R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
• Emma Meurling joined Bioinvent as Human Resource (HR) Director.
Events after the period
• BioInvent and Transgene announced that preclinical data for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors, will be presented at SITC in November 2021.
• New data on the lead drug candidate BI-1206 Phase 1/2a study in non-Hodgkin's lymphoma (NHL) to be presented at the ASH (American Society of Hematology) conference December 11-14.
• New production agreement with CRUK to produce additional batch of anti-HER3 antibody.
• Prof. Eggermont new member of the BioInvent Scientific Advisory Board.
Financial information
Third quarter 2021
• Net sales SEK 3.0 (16.3) million.
• Loss after tax SEK -62.6 (-32.9) million.
• Loss after tax per share before and after dilution SEK -1.07 (-1.00).
• Cash flow from operating activities -57.5 (-31.4) million.
January - September 2021
• Net sales SEK 14.5 (48.6) million.
• Loss after tax SEK -199.7 (-104.9) million.
• Loss after tax per share before and after dilution SEK -3.79 (-4.00).
• Cash flow from operating activities SEK -170.1 (-91.8) million.
• Liquid funds and long-term investments as of September 30, 2021: SEK 1,445.3 (642.1) million.
The complete report is attached as pdf and is available on the company's website www.bioinvent.com/investors/#financialreports.
(R)= Regulatory event
Contacts
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
About Us
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/670065/BioInvent-International-AB-Interim-Report-January--September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI and The Dream Bowl to Set New Benchmark in Sports Innovation with World’s First Tokenized Autograph Session, Featuring Current and Future NFL Stars - Live on ESPN+2.1.2026 19:50:00 CET | Press release
30 former NFL star players from different NFL Teams will autograph on-site up to 3,000 The Dream Bowl memorabilia items such as helmets, footballs, jerseys, and live-autographs by Notable Live. Autographed memorabilia items will be anchored by Prova & Sumerian technologies and digital twins will be tokenized with Data Vault. Digital tokens anchored to real The Dream Bowl autographed memorabilia items will be awarded [by lottery] to holders of the original Dream Bowl Meme Coin token (the "Dream Bowl Meme Coin I") and, following the distribution date of the Dream Bowl Meme Coin II tokens to certain record holders of Datavault AI securities as of January 7, 2026 (the "Dream Bowl Meme Coin II" and together with the Dream Bowl Meme Coin I, the "Dream Bowl Meme Coins"), to holders of the Dream Bowl Meme Coin II, throughout 2026 with an average of 10 winners selected every business day. Dream Bowl Meme Coins memorabilia digital tokens will be traded on Datavault AI's forthcoming International
Clean Air Metals Files Interim Financial Statements for the Nine Months Ended October 31, 202530.12.2025 03:20:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / December 29, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the nine-month period ended October 31, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at October 31, 2025 of $36,602,553 Total cash as at October 31, 2025 of $1,643,422 Working capital deficiency as at October 31, 2025 of $1,746,454 Shareholder's equity as at October 31, 2025 of $33,030,843 During the nine months ended October 31, 2025, the Company incurred $1,046,223 in cost for exploration activities at the TBN project. Key activities of the Company's management team this quarter included the completion of the initial drilling of the first step-out exploration target within the Escape down-plunge area, resulting in a mineralized intersection 400m from the known resource.
EESystem Files for Preliminary Injunction to Block Unauthorized Use of Proprietary Wellness Technology29.12.2025 17:15:00 CET | Press release
Legal action seeks to halt Jason Shurka and The Light System, Inc. from misappropriating EES intellectual property LAS VEGAS, NV / ACCESS Newswire / December 29, 2025 / Energy Enhancement System, LLC (EES), a global provider of advanced wellness technology, has taken decisive legal action to protect its proprietary innovations and the integrity of its licensed network. On December 22, 2025, EES filed a Motion for Preliminary Injunction in the U.S. District Court for the District of Nevada. The motion seeks to immediately enjoin defendants Jason Shurka and The Light System, Inc., operating via thelightsystems.com and unifydhealing.com, with events and personal bio promoted on jasonshurka.com, from the unauthorized use of EES's intellectual property. This filing is a critical step in defending the authenticity of the EE System technology, which powers an extensive global network with thousands of installations worldwide. The motion is supported by detailed evidence alleging contractual b
Launch of the 8th Global Conference on Occupational Safety and Health (GOSH 8) in RIYADH, SA - 202628.12.2025 13:30:00 CET | Press release
RIYADH, SA / ACCESS Newswire / December 28, 2025 / His Excellency Eng. Ahmed bin Sulaiman Al‑Rajhi, Minister of Human Resources and Social Development and Chairman of the National Council for Occupational Safety and Health, announced the launch of the 8th Global Conference on Occupational Safety and Health (GOSH8), scheduled to be held in 2026 under the theme "Sustainable Safety for a Prosperous Future." The conference will take place from 27 to 29 April 2026 at the Hilton Hotel in Riyadh, Saudi Arabia. During the announcement, His Excellency also inaugurated the official website of the 8th Global Conference on Occupational Safety and Health, which enables specialists and interested participants to register for the conference and access full details, including key themes, topics, and accompanying activities. The conference continues to play a leading role as an international scientific platform, dedicated to exploring the future of occupational safety and health, discussing global labo
Loar Holdings Inc. Announced The Completion of its Acquisition of LMB Fans & Motors26.12.2025 14:00:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / December 26, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar," "we," "our," or "the Company") today announced the completion of its acquisition of LMB Fans & Motors ("LMB") for €367 million, plus the assumption of debt, paid in cash at closing. Founded more than 60 years ago, LMB is a global leader in designing and manufacturing customized, high-performance fans and motors. With decades of expertise and nearly 100% of its revenue derived from proprietary designs, LMB offers over 2,000 unique products, including fans, blowers, motors, and specialized rotating machines. Its fans and brushless motors are widely used across aerospace and defense platforms. LMB employs more than 75 team members worldwide, including those at its headquarters and manufacturing facility in Malemort-sur-Corrèze, France. The transaction was completed following clearance under the French foreign direct investment screening procedure by the Ministry of Economy and Finance. L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom